Hypertension

CMS proposed to expand reimbursement for ambulatory blood pressure monitoring (ABPM) to patients with suspected masked hypertension while continuing to cover it for those with white coat hypertension.

A meta-analysis of sham-controlled renal denervation trials published in the Journal of the American College of Cardiology found the catheter-based procedure was associated with statistically significant drops in ambulatory and office blood pressure measurements among hypertensive patients.

People who reported waking up in the middle of the night to use the bathroom were 40 percent more likely to have hypertension, according to a study presented March 30 at the Japanese Circulation Society’s annual scientific meeting.

More than 85 percent of African-American men and women are likely to develop hypertension in their lifetimes based on the new cutoff for high blood pressure established in the 2017 U.S. guidelines, researchers reported March 27 in JAMA Cardiology.

In the largest-ever randomized trial of antihypertensive drug treatment in sub-Saharan Africa, two medication combinations including the long-acting calcium channel blocker amlodipine outperformed a third two-drug combination featuring a diuretic and an angiotensin-converting-enzyme (ACE) inhibitor.

Hypertensive patients from the RADIANCE-HTN SOLO trial who received renal denervation sustained a lower blood pressure through six months compared to participants randomized to a sham procedure, despite being placed on fewer antihypertensive medications during follow-up.

The CDC has released a new fact sheet on the burden of chronic kidney disease (CKD) in the U.S., highlighting its relationship to cardiovascular disease and noting that 15 percent of American adults—or 37 million people—have CKD.

The FDA fast-tracked the approval process for a new generic valsartan product (Diovan) amid an ongoing shortage of the blood pressure and heart failure medication.

A napping habit could lower blood pressure to a similar extent as other lifestyle modifications and some drugs, according to research scheduled to be presented March 18 at the American College of Cardiology’s scientific sessions in New Orleans.

The SPRINT trial suggested a more aggressive blood pressure-lowering target reduced the rate of cardiovascular events in hypertensive people, but a new secondary analysis of the trial indicates such an approach may actually be harmful for smokers.

In its first scientific statement on accurately measuring blood pressure in 14 years, the American Heart Association gave a stronger recommendation for oscillometric devices and updated the evidence surrounding ambulatory and home blood pressure monitoring techniques.

An ongoing FDA investigation of generic angiotensin II receptor blocker (ARB) drugs used to treat hypertension and heart failure found higher-than-acceptable levels of the carcinogen N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) in recent batches of losartan potassium tablets, prompting a voluntary recall of 87 lots, the agency announced March 1. NMBA is the third different carcinogenic impurity recently discovered in ARBs.